Xponance’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Xponance’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,011	Closed	-$216K	–	1314
2023 Q1	$216K	Buy	2,011 +20	+1%	+$2.3K	﹤0.01%	1113
2022 Q4	$219K	Buy	+1,991	New	+$129K	﹤0.01%	1104

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Xponance's RXDX Position: Q2 2023 in Review

Xponance sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 2,011 shares — an estimated $216K sold.

Xponance first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $219K in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Xponance reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Xponance sold 2,011 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $216K.
Xponance first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Xponance's Prometheus Biosciences, Inc. Common Stock position peaked at $219K in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Xponance's 13F filing for Q2 2023, filed 14 Jul 2023.